These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16265769)

  • 21. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk?
    Gilleece Y; Nelson M
    J HIV Ther; 2001 May; 6(2):37-9. PubMed ID: 11501202
    [No Abstract]   [Full Text] [Related]  

  • 22. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.
    Mellor-Pita S; Yebra-Bango M; Alfaro-Martínez J; Suárez E
    Clin Infect Dis; 2002 Mar; 34(5):716-7. PubMed ID: 11823959
    [No Abstract]   [Full Text] [Related]  

  • 24. Interaction between lopinavir/ritonavir and warfarin.
    Hughes CA; Freitas A; Miedzinski LJ
    CMAJ; 2007 Aug; 177(4):357-9. PubMed ID: 17698824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dyslipidemia caused by ritonavir].
    Mínguez C; Roca B; Usó J; Andrés J
    Med Clin (Barc); 1999 May; 112(17):677. PubMed ID: 10374192
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.
    Churchill DR; Pym AS; Babiker AG; Back DJ; Weber JN
    Br J Clin Pharmacol; 1998 Nov; 46(5):518-9. PubMed ID: 9833608
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV protease inhibitors and hyperlipidemia: a fatty acid connection.
    Spector AA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):7-9. PubMed ID: 16373621
    [No Abstract]   [Full Text] [Related]  

  • 28. [Possible cardiovascular complications. What leads to "switching"].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():82. PubMed ID: 12043091
    [No Abstract]   [Full Text] [Related]  

  • 29. Insulin resistance, HIV infection, and anti-HIV therapies.
    Taiwo BO
    AIDS Read; 2005 Apr; 15(4):171-6, 179-80. PubMed ID: 15844237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 32. Ritonavir and anemia in women.
    AIDS Patient Care STDS; 2000 Feb; 14(2):102. PubMed ID: 10743525
    [No Abstract]   [Full Text] [Related]  

  • 33. Protease inhibitors and body shape changes.
    TreatmentUpdate; 1998 Apr; 10(2):4-5. PubMed ID: 11365437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic complications in HIV infection. In search of underlying mechanisms.
    Johnson DL
    Adv Nurse Pract; 2002 Jul; 10(7):45-50, 76. PubMed ID: 12420551
    [No Abstract]   [Full Text] [Related]  

  • 35. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-protease inhibitors.
    Di Perri G; Del Bravo P; Concia E
    N Engl J Med; 1998 Sep; 339(11):773-4; author reply 774. PubMed ID: 9742031
    [No Abstract]   [Full Text] [Related]  

  • 37. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyponatraemia associated with lopinavir--ritonavir?
    Roberts MT; Aliyu SH
    Int J Infect Dis; 2007 Jan; 11(1):83-4. PubMed ID: 16574455
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.